22-Oxacalcitriol: Vitamin D3 analog treatment of hyperparathyroidism antipsoriatic antineoplastic

Drugs of the Future

Volumn 21, Issue 12, 1996, Pages 1229-1237

  Leeson, P A ^a   Martel, A M ^a   Castaner R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ANTINEOPLASTIC AGENT; ANTIPSORIASIS AGENT; CALCITRIOL; COLECALCIFEROL DERIVATIVE; PARATHYROID HORMONE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; DRUG DETERMINATION; DRUG SYNTHESIS; HUMAN; HYPERPARATHYROIDISM; NONHUMAN; PANCREAS CANCER; PSORIASIS; RADIOIMMUNOASSAY; SHORT SURVEY;

EID: 0030485528     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.12.384901     Document Type: Article

References (42)

1. Kubodera, N., Miyamoto, K., Ochi, K., Matsunaga, I., Murayama, E. (Chugai Pharm. Co., Ltd.). Novel vitamin D derive, and process for producing the same. EP 184112, JP 86267548, JP 86267550.
2. 3 analogues. Chem Pharm Bull 1986, 34: 4410-3.
3. 3 analogues. Chem Pharm Bull 1992, 40: 1494-9.
4. Kubodera, N. Active vitamin D analogs. Important and various roles by medicinal chemists during the course of development of promising candidates as useful medicines. Jpn J Org Chem 1996, 54: 139-45.
5. Kato, M., Mikami, T., Ochi, K., Watanabe, H., Kubodera, N. (Chugai Pharm. Co., Ltd.). 22-Oxacalciferol deriv. and production thereof. WO 9312083.
6. Mikami, T. (Chugai Pharm. Co., Ltd.). Vitamin D deriv. and process for producing the same. WO 9408958.
7. 3. J Label Compounds Radiopharm 1995, 36: 645-54.
8. Reichel, H., Koeffler, H.P., Norman, A.W. The role of the vitamin D endocrine system in health and disease. New Engl J Med 1989, 320: 980-91.
9. 3 of transcription of the parathyroid hormone gene. Endocrinology 1986, 119: 2864-6.
10. Berl, T., Berns, A.S., Huffler, W.E., Hammill, A.C., Alfrey, A.C., Arnaud, C.D., Shrier, R.W. 1,25-Dihydroxycholecalciferol effects in chronic dialysis: A double-blind controlled study. Ann Intern Med 1978, 88: 774-80.
11. Salusky, I.B., Fine, R.S., Kangarloo, H., Gold, R., Paunier, L., Goodman, W.G., Brill, J.E., Gilli, G., Slatopolsky, E., Coburn, J.W. "High-dose" calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 1987, 32: 89-95.
12. Abe, J., Morikawa, M., Miyamoto, K., Kaiho, S., Fukushima, M., Miyaura, C., Abe, E., Suda, T., Nishii, Y. Synthetic analogues of vitamin D3 with an oxygen atom in the side chain skeleton. FEBS Lett 1987, 226: 58-62
13. 3 analogue with antiangiogenic action. Drug News Perspect 1993, 6: 157-62.
14. 3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 1989, 124: 2645-7.
15. 3, inhibits the growth of human breast cancer in vitro and in vivo with-out causing hypercalcemia. Endocrinology 1991, 129: 832-7.
16. 3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 1996, 110: 1605-13.
17. 3 analogues in breast cancer cells. Cancer Res 1996, 56: 2789-94.
18. Abe-Hashimoto, J., Kikuchi, T., Matsumoto, T., Nishii, Y., Ogata, E., Ikeda, K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 1993, 53: 2534-7.
19. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anti-Cancer Drugs 1991, 2: 475-80.
20. 3 (OCT) as a single agent or combined therapy with aromatase inhibitor (CGS 16949A) on 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Int J Oncol 1996, 9: 79-82.
21. Brown, A.J., Finch, J.L., Lopez-Hilker, S., Dusso, A., Ritter, C., Pernalette, N., Slatopolsky, E. New active analogues of vitamin D with low calcemic action. Kidney Int 1990, 38(Suppl. 29): S22-7.
22. Brown, A.J., Ritter, C.R., Finch, J.L., Morrissey, J., Martin, K.J., Muramaya, E., Nishii, S., Slatopolsky, E. The non-catcemicanalog of vitamin D., 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989, 27: 728-32.
23. Fukagawa, M., Kaname, S.Y., Igarashi, T., Ogata, E., Kurokawa, K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991, 39: 874-81.
24. Naveh-Many, T., Silver, J. Effects of calcitriol, 22-oxacalcitriol, and calcipotriot on serum calcium parathyroid hormone gene expression. Endocrinology 1993, 133: 2724-8.
25. Takahashi, S., Furuichi, T., Yorozu, K., Aso, Y., Kubodera, N., Slatopolsky, E. Effect of intravenous 22-oxacalcitriol (OCT) and calcitriol on secondary hyperparathyroidism in dogs with chronic renal failure (CRF). J Amer Soc Nephrol 1994, 5(3): 890.
26. 3 (OCT) for the treatment of secondary hyperparathyroidism (2° HPT) in chronic renal failure (CRF) rats. J Amer Soc Nephrol 1994, 5(3): 857.
27. Friedlaender, M.M., Yagil, Y., Wald, H., Popovtzer, M.M. 22.Oxacalcitriol does not interfere with parathyroid hormone-induced phosphaturia or cyclic-AMP excretion. Bone 1995, 17: 301-6.
28. 3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996, 50: 34-9.
29. 3 and a new analogue, 22-oxacalcitriol modulate proliferation and interleukin-8 secretion in normal human keratinocytes. J Invest Dermatol 1996, 106(4): Abst 357.
30. 3 on carrageenin-induced inflammation in rats. Biol Pharm Bull 1994, 17: 1130-1.
31. 3, stimulates the production of prostacyclin by vascular tissues. Life Sci 1992, 51: 1105-12.
32. Matsuzaki, M., Shimamoto, Y., Watanabe, M., Kukita, A., Yoshida, S., Tadano, J. Intracellular multiplication of Legionella pneumophilia in HL-60 cells functionally differentiated in response to 22-oxacalcitriol. J Leukocyte Biol 1995, 57: 574-80.
33. 3, on bone mineral metabolism in normal male rats. Calcif Tissue Int 1992, 50: 521-3.
34. 3 on bone metabolism in young X-linked hypophosphatemic male mice. Amer J Physiol 1996, 270(1, Part 1): E141-7.
35. 3, significantly increases bone mass in ovariectomizedrats. Bone 1995,16(1, Suppl.): Abst 440.
36. Masuda, S., Byford, V., Kremer, R., Makin, H.L.J., Kubodera, N., Nishii, Y., Okazaki, A., Okano, T., Kobayashi, T., Jones, G. In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, usingcultured osteosarcoma, hepatoma, and keratinocyte cell lines. J Biol Chem 1996, 271: 8700-8.
37. 3. Bioorg Med Chem Lett 1994, 4: 753-6.
38. Kamimura, S., Gallieni, M., Kubodera, N., Nishii, S., Brown, A.J., Slatopolsky, E., Dusso, A. Differential catabolism of 22-oxacalcitriol and 1,25-dihydroxyvitamin D3 by normal human peripheral monocytes. Endocrinology 1993, 133: 2719-23.
39. 3, in rats. J Biochem 1994, 115: 373-80.
40. 3 having valuable clinical potency, in rat and human plasma. Biol Pharm Bull 1995, 18: 382-7.
41. Kurokawa, K., Akizawa, T., Suzuki, M., Akiba.T., Ogata, E., Slatopolsky, E. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study. Neph rol Dial Transplant 1996, 11 (Suppl. 3): 121-4.
42. Chugai Pharmaceutical Co., Ltd. Annual Report 1996.